Loading...
 
Translate Register Log In Login with facebookLogin and Register

Multiple Sclerosis risk of relapse reduced by 13 percent for every 2.5 ng higher level of vitamin D (under age 37) – June 2017

Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up

. PLoS ONE 11(6): e0156122. doi:10.1371/ journal.pone.0156122

VitaminDWiki comment

The Vitamin D benefit was only noticed in those < age 37
Suspect a similar benefit would be noticed for those having MS for a short time (< 5 years)
Only rarely can a modest level of Vitamin D undo the long-term ravages of a disease

See also VitaminDWiki

Overview MS and vitamin D contains the following summary

Clinical interventions have shown that Vitamin D can prevent, treat, and even cure Multiple Sclerosis, at a tiny fraction of the cost of the drugs now used to treat it, and without side effects.

Summary: lack of consensus on how much to prevent, treat, or cure MS.

  • How much Vitamin D to prevent many diseases - such as MS
  • How much Vitamin D is needed to treat MS? There is currently no agreement
       The recommendations range from 40 to 100 ng - which can result of a dose ranging from 3,000 to 20,000 IU/day
  • How Vitamin D is needed to Cure MS?: It appears that 20,000-140,000 IU daily may be needed to CURE the disease
       You must be under the supervision of a doctor who knows what to watch for in your individual situation.
       High doses of Vitamin D cannot be used as a monotherapy.
       You will need to adjust the cofactors: Typically increasing Magnesium and Vitamin K2, and reducing Calcium intake.
       Your doctor will monitor these and might increase your intake of Vitamins B2, C, as well as Omega-3


Multiple Sclerosis and (lots of) Vitamin D - book by patient on Coimbra protocol - Feb 2016 contains protocol description

Vitamin D Protocol used by Dr. Coimbra for Multiple Sclerosis etc.
Snips as of April 2016 http://www.vitamindprotocol.com/dr.-coimbra-s-ms-protocol.html

  • 1,000 IU's vitamin D per kilogram as a first approximation
    (apparently increased/decreased depending of resulting vitamin D blood level)
  • Vitamin B2, magnesium glycinate, boron, chromium picolinate, Omega 3 DHA, Zinc, Methylcobalamin form of B12, Choline, etc.
  • Lack of B12 may affect 10%–15% of the general population and may be the most prevalent genetic risk factor for several human diseases
  • Discontinue eating or drinking dairy products or calcium enriched foods or beverages, also no Ca supplements
  • Drink as least 2.5 liters [85 ounces] of fluids, preferably water
  • Required Tests:​ Vitamin D, Parathyroid, Blood calcium, urinary calcium


 Download the PDF from VitaminDWiki

Anne-Hilde Muris1,2*, Joost Smolders20, Linda Rolf1,2, Lieke J. J. Klinkenberg3,
Noreen van der Linden3, Steven Meex3, Jan Damoiseaux3, Raymond Hupperts1,2
1 School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, the Netherlands,
2 Academic MS Center Limburg, Zuyderland Medical Center, Sittard, the Netherlands,
3 Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, the Netherlands
a Current address: Department of Neurology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands * a.muris at maastrichtuniversity.nl

Background and Objective
The risk of developing multiple sclerosis (MS) as well as MS disease activity is associated with vitamin D (25(OH)D) status. The relationship between the main functional disability hallmark of MS, disability progression, and 25(OH)D status is less well established though, especially not in MS patients with progressive disease.

Methods
This retrospective follow-up study included 554 MS patients with a serum baseline 25(OH) D level and Expanded Disability Status Scale (EDSS) with a minimum follow-up of three years. Logistic regressions were performed to assess the effect of baseline 25(OH)D status on relapse rate. Repeated measures linear regression analyses were performed to assess the effect on disability and disability progression.

Results
Baseline deseasonalized 25(OH)D status was associated with subsequent relapse risk (yes/no), but only in the younger MS patients (< 37.5 years; OR = 0.872, per 10 nmol/L 25 (OH)D, p = 0.041). Baseline 25(OH)D status was not significantly associated with either disability or disability progression, irrespective of MS phenotype.

Conclusion
Within the physiological range, 25(OH)D status is just significantly associated with the occurrence of relapses in younger MS patients, but is not associated with disability or disability progression over three years follow-up. Whether high dose supplementation to supra physiological 25(OH)D levels prevents disability progression in MS should become clear

Created by admin. Last Modification: Tuesday July 18, 2017 21:07:02 GMT-0000 by admin. (Version 3)

Attached files

ID Name Comment Uploaded Size Downloads
8197 MS RR.pdf PDF 2017 admin 18 Jul, 2017 20:58 781.72 Kb 90
See any problem with this page? Report it (FINALLY WORKS)